Business ❯ Biotechnology ❯ Pharmaceuticals

Regulatory Affairs

FDA Approval ImmunityBio, Inc. Product Development

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

Published long-term outcomes alongside rising revenue strengthen the case for a papillary NMIBC label.

FDA Opens Door to Reconsider Capricor’s Duchenne Cell Therapy Based on HOPE-3 Data